Funder: Alzheimer's Association

Due Dates: August 6, 2025 (LOI) | September 24, 2025 (Full Application, by invitation)

Funding Amounts: Up to $1,000,000 for Phase 1 studies; up to $2,000,000 for Phase 2 studies (over 2–3 years)

Summary: Supports early-phase (Phase 1 & 2) clinical trials of gene-targeted therapies addressing the genetic causes of Alzheimer's and related dementias.

Key Information: Open to global applicants from academic and small for-profit organizations; LOI required.